Honored with Frost & Sullivan’s Global Product Leadership Award for leading the critical-care immunotherapy segment in blood purification, CytoSorbents Corporation is currently distributing its EU-approved CytoSorb cytokine adsorber in 75 countries around the world. CytoSorb® is helping to treat life-threatening conditions in the intensive care unit and cardiac surgery. One major application is the reduction of cytokine storm, with the goal of reducing severe inflammation and serious complications such as organ failure—the leading cause of death in the ICU today, while improving patient outcomes and reducing overall costs of critical care. Another newer application is the reduction of antithrombotic agents, often called “blood thinners,” during open heart surgery, with the goal of reducing unwanted perioperative bleeding.

Data Provided by Refinitiv.
Minimum 15 minutes delayed.

Press Release

02 Jul '24
Credit facility provides timely non-dilutive capital to support ongoing global commercialization of CytoSorb® as well as regulatory submissions and potential commercialization plans for DrugSorb™-ATR in the U.S. and Canada PRINCETON, N.J. , July 02, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation...
24 Jun '24
Brings a powerful blood purification technology used to treat critically ill and cardiac surgery patients in nearly a quarter million treatments across 75 countries to date to one of the most progressive healthcare systems in the world PRINCETON, N.J....

Upcoming Events

More events are coming soon.

Featured Reports